Filing Analysis
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2026. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- Reporting date: July 28, 2026
- Period covered: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the press release of financial results.
Nautilus Biotechnology, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company successfully met the criteria by maintaining a closing bid price at or above $1.00 for ten consecutive business days, resolving the delisting risk.
🚩 Red Flags
- Historical non-compliance with minimum bid price requirements (March–April 2025) indicates past extreme volatility or liquidity issues.
📋 Key Facts
- The Company received written notice from Nasdaq on November 3, 2025, confirming it has regained compliance with Listing Rule 5550(a)(2).
- Compliance was achieved by meeting or exceeding a $1.00 closing bid price for at least ten consecutive business days.
- The company previously faced delisting risk due to failing the minimum bid price requirement between March 19, 2025, and April 30, 2025.
- Nautilus transferred from Nasdaq Global Select Market to Nasdaq Capital Market on October 29, 2025, during its compliance period.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reporting period: Quarter ended September 30, 2025.
- Filing date: October 28, 2025.
- The company is an emerging growth company.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Reporting date: July 31, 2025
- Period covered: Quarter ended June 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'Emerging Growth Company'
Nautilus Biotechnology, Inc. held its 2025 annual meeting of stockholders on June 20, 2025. The filing reports the election of new directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
🚩 Red Flags
- Departure of two former directors (Vijay Pande and Michael Altman).
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- 99,716,163 shares (approx. 79% of outstanding common stock) were represented at the meeting.
- Sujal Patel and Matthew McIlwain elected to serve as Class I directors until 2028.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year ending Dec 31, 2025.
- Directors Vijay Pande and Michael Altman resigned from the Board effective upon the Annual Meeting.
- Board approved decreasing the authorized number of directors to seven (7) directorships.
Nautilus Biotechnology, Inc. received a deficiency notice from Nasdaq because its stock price fell below the $1.00 minimum bid requirement for 30 consecutive business days. The company has been granted a 180-day compliance period ending October 28, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum bid price requirement ($1.00)
- Potential for mandatory reverse stock split to regain compliance
- Risk of delisting if compliance is not met by October 28, 2025
📋 Key Facts
- Deficiency Period: March 19, 2025, through April 30, 2025.
- Reason for deficiency: Closing bid price fell below $1.00 per share (Nasdaq Listing Rule 5450(a)(1)).
- Compliance Deadline: October 28, 2025 (180-day period).
- Requirement to cure: Maintain a closing bid price of at least $1.00 for 10 consecutive business days.
- Potential remedy mentioned: A reverse stock split may be required if the company seeks a second compliance period via transfer to Nasdaq Capital Market.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- Reporting date: April 29, 2025
- Financial period covered: Quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Company is classified as an 'emerging growth company'.
Nautilus Biotechnology reported its Q4 and FY2024 financial results and announced significant changes to its Board of Directors structure. Two directors (Vijay Pande and Michael Altman) will not stand for re-election, leading to a reduction in the authorized number of board seats from eight to seven.
🚩 Red Flags
- Departure of two directors (Pande and Altman) simultaneously may indicate shifts in strategic direction or governance changes.
📋 Key Facts
- Company issued press release reporting financial results for the quarter and fiscal year ended December 31, 2024 (Item 2.02).
- Vijay Pande and Michael Altman will not stand for re-election at the 2025 annual meeting of stockholders.
- Matthew McIlwain is resigning as a Class II director to stand for election as a Class I director to maintain board class balance.
- The Board approved decreasing the authorized number of directors from eight to seven, effective upon the opening of polls at the Annual Meeting.
Nautilus Biotechnology, Inc. announced that two directors, Vijay Pande and Michael Altman, will not stand for re-election at the 2025 annual meeting of stockholders.
📋 Key Facts
- Vijay Pande informed the Company on January 27, 2025, that he will not stand for re-election.
- Michael Altman informed the Company on January 28, 2025, that he will not stand for re-election.
- Both directors confirmed their decisions are not due to any disagreements with the Company regarding operations, policies, or practices.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reporting period: Quarter ended September 30, 2024.
- Filing date: October 29, 2024.
- The company is classified as an 'emerging growth company'.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Financial results reported are for the quarter ended June 30, 2024.
- The company is classified as an 'emerging growth company'.
- Press release dated July 30, 2024, is attached as Exhibit 99.1.
Nautilus Biotechnology, Inc. held its 2024 annual meeting of stockholders on June 13, 2024. The filing reports the results of shareholder votes regarding the election of Class III directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Total shares outstanding as of record date (April 16, 2024): 125,265,015.
- Shares represented at meeting: 105,300,784 (approx. 84% of outstanding shares).
- Melissa Epperly, Matthew L. Posard, and Karen Akinsanya were elected to the Class III Board of Directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024.
📋 Key Facts
- Report date: April 30, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard earnings release under Item 2.02
- Company is classified as an emerging growth company
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2023.
📋 Key Facts
- Reported financial results for the quarter and fiscal year ended December 31, 2023.
- The filing was made on February 28, 2024.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Nautilus Biotechnology entered into an 'at the market' (ATM) sales agreement with TD Cowen to sell up to $125 million in common stock. This allows the company to raise capital incrementally through a shelf registration statement.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings can create downward pressure on the share price during execution.
📋 Key Facts
- Entered into a Sales Agreement with Cowen and Company, LLC on February 28, 2024.
- Aggregate sales proceeds of up to $125,000,000 in common stock.
- The offering is an 'at the market' (ATM) program under Rule 415.
- TD Cowen will receive compensation of up to 3.0% of gross proceeds.
- Sales are subject to a shelf registration statement on Form S-3 filed on February 28, 2024.